Phospho-EZR (T566) Antibody

What is Phospho-EZR (T566) Antibody and what does it detect?

Phospho-EZR (T566) Antibody is a specialized immunological reagent that specifically detects ezrin protein only when phosphorylated at the threonine 566 position. This antibody recognizes the phosphorylated form of ezrin without cross-reactivity to other proteins, making it valuable for studying ezrin's phosphorylation state in various biological contexts. The antibody is typically produced by immunizing rabbits with synthesized peptides derived from human ezrin protein surrounding the phosphorylation site of Thr566 . The resulting polyclonal antibody preparation is then affinity-purified to ensure specificity for the phosphorylated epitope. This high level of specificity allows researchers to distinguish between the active (phosphorylated) and inactive forms of ezrin in experimental systems, providing crucial information about signaling pathways and cellular processes involving ezrin regulation.

What is the biological significance of ezrin phosphorylation at T566?

Ezrin phosphorylation at T566 (equivalent to T567 in some research literature) represents a critical regulatory mechanism for ezrin function in connecting cytoskeletal structures to the plasma membrane. When phosphorylated at this position, ezrin undergoes conformational changes that promote its activation and involvement in various cellular processes. Research has demonstrated that phosphorylation at this site is particularly important in epithelial cells, where it facilitates the formation of microvilli and membrane ruffles on the apical pole . Additionally, phosphorylated ezrin at T566/T567 has been implicated in cancer metastasis, particularly in hepatocellular carcinoma, where it promotes cell invasion capabilities by enhancing cytoskeletal-membrane remodeling . The phosphorylation state of ezrin thus serves as a molecular switch that regulates its participation in normal cellular architecture as well as pathological processes like cancer progression and metastasis.

What applications can Phospho-EZR (T566) Antibody be used for?

Phospho-EZR (T566) Antibody has been validated for several common laboratory applications:

• Western Blotting (WB): The antibody can be used at dilutions ranging from 1:500-1:2000 for detecting phosphorylated ezrin in protein lysates separated by gel electrophoresis . This application is particularly useful for quantitative assessment of phosphorylation levels across different experimental conditions.

• Enzyme-Linked Immunosorbent Assay (ELISA): The antibody performs well in ELISA applications at dilutions of approximately 1:2000 (Boster Bio recommendation) to 1:10,000 (Immunological Sciences recommendation) . ELISA provides a high-throughput method for quantifying phospho-ezrin levels in multiple samples.

• Immunohistochemistry (IHC): Although not explicitly listed in all product descriptions, phospho-ezrin antibodies have been successfully employed in immunohistochemical analyses of paraffin-embedded tissues, as demonstrated in research studies examining ezrin phosphorylation in cancer tissues .

When designing experiments utilizing this antibody, researchers should begin with the recommended dilutions and optimize based on their specific experimental systems and detection methods.

What species does the Phospho-EZR (T566) Antibody react with?

The Phospho-EZR (T566) Antibody shows reactivity across multiple mammalian species, making it versatile for comparative studies. According to product specifications, the antibody reliably detects phosphorylated ezrin in:

• Human (Hu) samples

• Mouse (Ms) samples

• Rat (Rt) samples

This cross-species reactivity is particularly valuable for researchers conducting translational studies that bridge findings between animal models and human systems. The conservation of the phosphorylation site across these species reflects the evolutionary importance of this regulatory mechanism. When working with samples from species not explicitly listed, researchers should perform validation tests to confirm antibody specificity and reactivity before proceeding with full-scale experiments.

How should Phospho-EZR (T566) Antibody be stored to maintain optimal activity?

Proper storage of Phospho-EZR (T566) Antibody is crucial for maintaining its specificity and sensitivity over time. Based on manufacturer recommendations:

• Long-term storage: Store the antibody at -20°C for up to one year . This temperature effectively preserves antibody activity while preventing degradation.

• Short-term/frequent use: For ongoing experiments requiring regular access to the antibody, storage at 4°C for up to one month is acceptable .

• Avoid repeated freeze-thaw cycles: Multiple freeze-thaw cycles can significantly reduce antibody performance by causing protein denaturation and aggregation .

The antibody is typically supplied in a stabilizing buffer containing PBS with 50% glycerol, 0.5% BSA, and 0.02% sodium azide . This formulation helps maintain antibody integrity during storage. When handling the antibody, researchers should aliquot the stock solution into smaller volumes upon receipt to minimize the number of freeze-thaw cycles each portion experiences, thereby extending the useful life of the reagent.

How can I differentiate between phosphorylation at T566 and other ezrin phosphorylation sites in complex samples?

Distinguishing between different ezrin phosphorylation sites requires careful experimental design and validation:

• Two-dimensional gel electrophoresis (2D-GE): This technique separates proteins based on both molecular weight and isoelectric point, allowing for the resolution of different phosphorylated forms of ezrin. Research has shown that phosphorylated ezrin appears as multiple spots on 2D gels, with phospho-T567 (equivalent to T566) predominantly appearing in specific spots (typically spots #2 and #3) . This pattern can be used as a signature to identify T566/T567 phosphorylation.

• Sequential immunoblotting: Perform initial blotting with the phospho-T566 specific antibody, then strip and reprobe the same membrane with antibodies against other phospho-sites (such as phospho-Y353) . Comparative analysis of the signal patterns can reveal the distribution of different phosphorylation states.

• Phosphatase treatment controls: Include controls where samples are treated with phosphatases prior to analysis. This removes all phosphorylation and should eliminate signal from phospho-specific antibodies, confirming specificity.

• Mutant protein expression: In cellular systems, express ezrin variants with mutations at specific phosphorylation sites (e.g., T566A or T566D phospho-mimetic mutations) to validate antibody specificity and distinguish between phosphorylation events .

By combining these approaches, researchers can confidently identify and quantify T566 phosphorylation distinct from other post-translational modifications of ezrin.

What is the relationship between Rho kinase activity and ezrin T566 phosphorylation in cancer metastasis?

Research has established a significant mechanistic link between Rho kinase (ROCK) activity and ezrin phosphorylation at T566/T567 in the context of cancer metastasis:

• Direct phosphorylation: Experimental evidence indicates that ROCK can directly phosphorylate ezrin at T567 (equivalent to T566), as demonstrated by reduced phosphorylation levels following ROCK inhibition with either chemical inhibitors (Y27632) or RNA interference approaches .

• Functional consequences: Phosphorylation of ezrin at T567 by ROCK promotes cytoskeletal-membrane remodeling, resulting in increased formation of membrane ruffles, which are structures associated with enhanced cell motility and invasiveness .

• Invasion assays: Hepatocellular carcinoma cells expressing wild-type ezrin show enhanced invasive capability, which is further increased when expressing phospho-mimicking mutant ezrin T567D. Conversely, expression of non-phosphorylatable ezrin T567A reduces invasion capacity, demonstrating the functional importance of this phosphorylation event .

• Inhibition studies: Treatment with ROCK inhibitors produces a dose-dependent reduction in ezrin T567 phosphorylation, correlating with decreased cancer cell invasion. Importantly, cells expressing the phospho-mimicking ezrin T567D mutant remain invasive even when ROCK is inhibited, confirming that ezrin phosphorylation is a downstream effector in this pathway .

This ROCK-ezrin signaling axis represents a potential therapeutic target for reducing metastasis in certain cancers, particularly hepatocellular carcinoma where this pathway has been well-characterized.

How do ezrin phosphorylation patterns differ between normal tissues and metastatic cancer samples?

The phosphorylation profile of ezrin exhibits distinctive patterns when comparing normal tissues to primary tumors and metastatic samples:

• Normal tissues: In normal liver tissue, minimal to undetectable levels of phosphorylated ezrin at T567 (equivalent to T566) have been observed using phospho-specific antibodies . This suggests that ezrin remains predominantly in an inactive conformation under normal physiological conditions.

• Primary tumors: Primary hepatocellular carcinoma samples show slightly increased levels of phospho-T567 ezrin compared to normal tissue, but the elevation is relatively minor .

• Metastatic samples: Cancer emboli and metastatic lesions demonstrate significantly elevated phospho-T567 ezrin levels compared to both normal tissue and primary tumors. Two-dimensional gel electrophoresis reveals distinctive patterns, with metastatic samples showing concentrated phosphorylation in specific ezrin isoform spots (particularly spots #2 and #3) .

• Tissue distribution: In normal brain tissue, ezrin expression varies by region, with stronger expression in gray matter of the frontal lobe compared to white matter, and preferential expression in astrocytes of various brain regions including hippocampus, frontal cortex, and thalamus. Importantly, ezrin is not typically detected in neurons in most tissues studied .

These differential patterns suggest that ezrin phosphorylation represents a dynamic process that progressively increases during cancer progression and metastasis, potentially serving as a biomarker for disease advancement and a target for therapeutic intervention.

What are the optimal protocols for detecting phospho-ezrin (T566) using Western blotting?

For optimal detection of phospho-ezrin (T566) by Western blotting, researchers should follow these methodological recommendations:

Sample Preparation:

• Extract proteins using a lysis buffer containing phosphatase inhibitors to preserve the phosphorylation state.

• Quantify protein concentration and load equal amounts (typically 20-50 μg) per lane.

Electrophoresis and Transfer:

• Separate proteins on 8-10% SDS-PAGE gels (ezrin has a molecular weight of approximately 69 kDa) .

• Transfer to PVDF or nitrocellulose membranes using standard protocols.

Antibody Incubation:

• Block membranes in 5% non-fat milk or BSA in TBST for 1 hour at room temperature.

• Incubate with Phospho-EZR (T566) Antibody at dilutions of 1:500-1:2000 (Boster Bio recommendation) or 1:1000 (Immunological Sciences recommendation) in blocking buffer overnight at 4°C.

• Wash membranes 3-5 times with TBST.

• Incubate with appropriate HRP-conjugated secondary antibody (anti-rabbit IgG) for 1 hour at room temperature.

• Wash membranes 3-5 times with TBST.

Detection:

• Develop using enhanced chemiluminescence (ECL) reagents.

• For quantitative analysis, normalize phospho-ezrin signal to total ezrin protein levels by stripping and reprobing with a total ezrin antibody.

Validation Controls:

• Include positive controls (samples known to contain phospho-ezrin, such as certain cancer cell lines).

• Include phosphatase-treated negative controls to confirm specificity.

• Consider including samples from cells treated with phosphorylation inhibitors as additional controls.

This protocol provides a reliable foundation for detecting phospho-ezrin, which can be optimized based on specific laboratory conditions and equipment.

How can I optimize antigen retrieval for phospho-ezrin (T566) in immunohistochemistry?

Effective antigen retrieval is critical for successfully detecting phospho-ezrin in tissue sections by immunohistochemistry. Based on published methodologies:

Heat-Induced Epitope Retrieval (HIER) Protocol:

• Prepare sections: Cut paraffin-embedded tissues into 4 μm-thick sections and mount on silane-coated slides .

• Deparaffinize and rehydrate: Process slides through xylene and graded alcohols according to standard protocols.

• Block endogenous peroxidase: Incubate sections with 3% H₂O₂ in methanol for 10 minutes at room temperature .

• Antigen retrieval: Place slides in 10 mM sodium citrate buffer (pH 6.0) and heat at 95°C for 20 minutes . This temperature and duration have been experimentally validated for phospho-ezrin detection.

• Cool slides: Allow to cool to room temperature in the retrieval solution for approximately 20 minutes.

• Blocking: Apply protein blocking solution to reduce non-specific binding.

• Primary antibody incubation: Incubate with Phospho-EZR (T566) Antibody at appropriate dilution (typically 1:150 based on similar phospho-ezrin antibodies) overnight at 4°C.

Optimization Considerations:

• Buffer composition: While citrate buffer (pH 6.0) has been validated, alternative buffers like EDTA (pH 9.0) may be tested if signal is suboptimal.

• Retrieval time: Adjust between 15-30 minutes if standard protocol yields inadequate results.

• Signal amplification: Consider using polymer-based detection systems for enhanced sensitivity.

• Positive controls: Include tissues known to express phospho-ezrin, such as metastatic cancer samples .

This optimized protocol enhances epitope accessibility while preserving tissue morphology, allowing for reliable detection of phospho-ezrin in histological specimens.

What experimental controls should be included when studying ezrin phosphorylation in cell-based assays?

When investigating ezrin phosphorylation in cellular systems, incorporating appropriate controls is essential for generating reliable and interpretable data:

Essential Controls for Cell-Based Phosphorylation Studies:

• Phosphorylation State Controls:

  • Positive control: Cells treated with known stimulators of ezrin phosphorylation (e.g., growth factors or phorbol esters)

  • Negative control: Cells treated with phosphatase inhibitors or kinase inhibitors (e.g., Y27632 for ROCK inhibition)

  • Phosphatase-treated samples: Lysates treated with lambda phosphatase to remove all phosphorylation as antibody specificity controls

• Genetic Manipulation Controls:

  • Wild-type ezrin overexpression: To establish baseline phosphorylation levels

  • Phospho-null mutant (T566A): Should show no signal with phospho-specific antibody

  • Phospho-mimetic mutant (T566D): Should maintain function even when kinases are inhibited

  • Ezrin knockdown: siRNA or shRNA to reduce total ezrin as specificity control

• Experimental Technique Controls:

  • Loading controls: Probing for housekeeping proteins (β-actin, GAPDH) or total ezrin

  • Antibody controls: Isotype control antibodies (rabbit IgG) to identify non-specific binding

  • Secondary antibody only: To detect potential background signal

  • Cross-reactivity assessment: Validation in cells from different species if working across species

• Functional Validation:

  • Phenotypic assays (e.g., invasion assays, membrane ruffle formation) to correlate phosphorylation status with biological outcomes

  • Dose-response experiments with kinase inhibitors to establish relationship between kinase activity and ezrin phosphorylation levels

Implementing these controls ensures that observed changes in ezrin phosphorylation are specific, reproducible, and biologically relevant, allowing for confident interpretation of experimental results.

How can I address weak or inconsistent signals when detecting phospho-ezrin (T566)?

Weak or inconsistent phospho-ezrin detection is a common challenge that can be addressed through systematic troubleshooting:

Sample Preparation Issues:

• Phosphorylation preservation: Ensure samples are processed rapidly and include phosphatase inhibitors (e.g., sodium fluoride, sodium orthovanadate, and phosphatase inhibitor cocktails) in all buffers.

• Protein degradation: Add protease inhibitors to lysis buffers and maintain samples at 4°C during processing.

• Lysis conditions: Use buffers containing 1% NP-40 or Triton X-100 with SDS to effectively solubilize membrane-associated ezrin.

Technical Optimization:

• Antibody concentration: If signal is weak, try higher antibody concentrations (up to 1:500 for Western blot) or longer incubation times.

• Blocking reagent: Switch from milk to BSA for blocking and antibody dilution, as milk contains phosphatases that may reduce phospho-epitopes.

• Detection system: Use more sensitive detection methods such as enhanced chemiluminescence (ECL) plus or super-signal reagents.

• Exposure time: For Western blots, optimize exposure times to capture signals without saturation.

Biological Considerations:

• Baseline phosphorylation: Some cell types or tissues may have naturally low levels of ezrin phosphorylation at T566. Consider treatments that increase phosphorylation, such as growth factor stimulation.

• Temporal dynamics: Phosphorylation may be transient; perform time-course experiments to identify optimal time points for detection.

• Subcellular localization: Phosphorylated ezrin may concentrate in specific cellular compartments; consider fractionation approaches to enrich for relevant compartments.

Validation Approaches:

• Alternative antibodies: Compare results with independent phospho-ezrin antibodies from different suppliers.

• Immunoprecipitation: Enrich for ezrin before probing for phosphorylation to increase detection sensitivity.

• Phosphatase controls: Treat duplicate samples with phosphatases to confirm specificity of any detected signals.

Implementing these strategies in a systematic manner will help identify and resolve issues affecting phospho-ezrin detection.

How do I interpret changes in ezrin phosphorylation in the context of complex signaling networks?

Interpreting ezrin phosphorylation data requires consideration of broader signaling contexts and careful experimental design:

Integrated Analysis Strategies:

• Multi-site phosphorylation assessment:

  • Ezrin function is regulated by phosphorylation at multiple sites, including T566/T567 and Y353

  • Compare phosphorylation patterns across sites to understand the complete activation state

  • Consider how different phosphorylation events may interact or sequentially occur

• Upstream kinase activity:

  • Correlate ezrin phosphorylation with activity of upstream kinases like ROCK

  • Use specific kinase inhibitors (e.g., Y27632 for ROCK) to establish causative relationships

  • Implement genetic approaches (siRNA, dominant-negative constructs) to confirm kinase specificity

• Downstream functional outcomes:

  • Link phosphorylation changes to relevant cellular phenotypes

  • For example, in cancer studies, correlate with invasion capacity, membrane ruffle formation, or metastatic potential

  • Use phospho-mimetic (T566D) and phospho-null (T566A) mutants to confirm functional significance

• Temporal dynamics and spatial organization:

  • Assess how quickly phosphorylation occurs after stimulation

  • Determine if phosphorylated ezrin redistributes within the cell

  • Consider co-localization with binding partners or relevant cellular structures

• Comparative analysis across experimental models:

  • Compare findings in cell lines versus primary tissues

  • Consider species differences when translating between animal models and human samples

  • Evaluate consistency across normal, primary tumor, and metastatic contexts

Data Presentation Recommendations:

• Quantify phospho-ezrin relative to total ezrin, not just as absolute phosphorylation levels

• Present data from multiple experimental approaches (Western blot, immunohistochemistry, functional assays)

• Include appropriate statistical analyses to distinguish significant changes from experimental variation

This integrated approach to data interpretation places ezrin phosphorylation within its proper biological context and strengthens the translational relevance of experimental findings.

What factors might lead to false-positive or false-negative results when using Phospho-EZR (T566) Antibody?

Recognizing potential sources of error is critical for accurate interpretation of phospho-ezrin data:

Causes of False-Positive Results:

• Cross-reactivity issues:

  • Antibody may recognize similar phosphorylation motifs in related proteins (e.g., radixin, moesin)

  • Validate specificity using ezrin knockout/knockdown samples

  • Confirm results with multiple antibodies from different sources or epitope targets

• Non-specific binding:

  • Insufficient blocking or inappropriate blocking reagents

  • High antibody concentrations leading to background signal

  • Secondary antibody binding to endogenous immunoglobulins in tissue samples

• Retention of phosphorylation during processing:

  • Inadequate fixation allowing post-mortem phosphorylation events

  • Sample processing artifacts, particularly in tissues with long ischemic times

  • Endogenous phosphatase activity variability between samples

Causes of False-Negative Results:

• Epitope masking:

  • Incomplete antigen retrieval in fixed tissues

  • Protein-protein interactions blocking antibody access to the phosphorylation site

  • Conformation changes in ezrin that hide the phosphorylated residue

• Phosphorylation loss:

  • Inadequate phosphatase inhibition during sample preparation

  • Delay between sample collection and processing

  • Repeated freeze-thaw cycles degrading phospho-epitopes

• Technical limitations:

  • Insufficient antibody concentration or incubation time

  • Incompatible detection systems or suboptimal imaging parameters

  • Buffer compositions that destabilize antibody-epitope interactions

Mitigation Strategies:

Implementing these controls and being aware of these potential pitfalls will improve data quality and reliability when studying ezrin phosphorylation in various experimental contexts.